Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 5/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042834 | 1.00 | HSD17B3 (0.47) | HSD17B3NOTUMP2RX4P2RX1P2RX3 | |
| SCHEMBL5048234 | 0.83 | HSD17B3 (0.52) | HSD17B3NOTUMP2RX4P2RX1P2RX3 | |
| SCHEMBL5048241 | 0.83 | HSD17B3 (0.52) | HSD17B3NOTUMP2RX4P2RX1P2RX3 | |
| SCHEMBL5038805 | 0.79 | HSD17B3 (0.45) | HSD17B3NOTUMP2RX4P2RX1P2RX3 | |
| SCHEMBL5038806 | 0.79 | HSD17B3 (0.45) | HSD17B3NOTUMP2RX4P2RX1P2RX3 | |
| SCHEMBL5039269 | 0.78 | HSD17B3 (0.50) | HSD17B3NOTUMP2RX4P2RX1P2RX3 | |
| SCHEMBL5039264 | 0.78 | HSD17B3 (0.50) | HSD17B3NOTUMP2RX4P2RX1P2RX3 | |
| SCHEMBL4798382 | 0.78 | HSD17B3 (0.71) | HSD17B3NOTUMP2RX4P2RX1P2RX3 | |
| SCHEMBL4798373 | 0.78 | HSD17B3 (0.71) | HSD17B3NOTUMP2RX4P2RX1P2RX3 | |
| SCHEMBL5038787 | 0.77 | HSD17B3 (0.55) | HSD17B3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725565-B1 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-1725565-B1 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B1, HSD17B2 | HSD17B3 1/4885NOTUM 907/4885P2RX4 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.